BAILLIE GIFFORD & COMPANY

stated that they own 9.2% of Juno Therapeutics Inc (NASDAQ:JUNO) in a Form 13G/A disclosure that was filed with the Securities and Exchange Commission (SEC) on Wednesday, January 10th. The investor owns 10,547,798 shares of the stock valued at about $519,057,140. The filing is available through EDGAR at this link.

BAILLIE GIFFORD & COMPANY

provided the following explanation of their ownership:

Other hedge funds and other institutional investors also recently modified their holdings of the company. The Manufacturers Life Insurance Company lifted its stake in shares of Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 228 shares during the last quarter. Pacad Investment Ltd. purchased a new stake in Juno Therapeutics in the second quarter valued at about $105,000. Advisor Group Inc. raised its stake in Juno Therapeutics by 141.1% in the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,439 shares during the last quarter. QS Investors LLC purchased a new stake in Juno Therapeutics in the second quarter valued at about $135,000. Finally, Bronfman E.L. Rothschild L.P. raised its stake in Juno Therapeutics by 27,376.9% in the third quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 3,559 shares during the last quarter. Hedge funds and other institutional investors own 69.94% of the company’s stock.

In related news, CFO Steve Harr sold 8,750 shares of Juno Therapeutics stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $44.76, for a total transaction of $391,650.00. Following the transaction, the chief financial officer now owns 772,082 shares in the company, valued at $34,558,390.32. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Richard Klausner sold 36,000 shares of Juno Therapeutics stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $44.76, for a total value of $1,611,360.00. Following the transaction, the director now owns 744,392 shares in the company, valued at approximately $33,318,985.92. The disclosure for this sale can be found here. Insiders sold 65,956 shares of company stock worth $3,064,378 over the last ninety days. Corporate insiders own 15.08% of the company’s stock.

Shares of Juno Therapeutics Inc (NASDAQ JUNO) opened at $49.21 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77. The stock has a market capitalization of $5,610.00, a P/E ratio of -14.52 and a beta of 2.32. Juno Therapeutics Inc has a 12 month low of $18.90 and a 12 month high of $63.45.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.80) by $0.07. The firm had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The business’s revenue was up 115.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.57) earnings per share. research analysts predict that Juno Therapeutics Inc will post -4.02 EPS for the current fiscal year.

JUNO has been the subject of a number of research analyst reports. Raymond James Financial increased their price target on Juno Therapeutics from $45.00 to $61.00 and gave the company an “outperform” rating in a research note on Friday, November 3rd. Zacks Investment Research cut Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Citigroup restated a “buy” rating and issued a $59.00 price objective on shares of Juno Therapeutics in a research note on Tuesday, October 31st. Wells Fargo & Co cut Juno Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, December 12th. Finally, Wedbush restated an “outperform” rating and issued a $64.00 price objective (up from $42.00) on shares of Juno Therapeutics in a research note on Thursday, November 2nd. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company. Juno Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $46.70.

ILLEGAL ACTIVITY NOTICE: “9.2% Stake of Juno Therapeutics Inc (JUNO) Maintained by BAILLIE GIFFORD & COMPANY” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.watchlistnews.com/9-2-stake-of-juno-therapeutics-inc-juno-maintained-by-baillie-gifford-company/1801237.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Institutional Ownership by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.